(click here for competition photo gallery)
Has been updated December 7, 2022
trenton, new jersey, December 7, 2022 /PRNewswire/ — BioNJ, of new jersey life sciences industry associations Health Equity in First Clinical Trial MBA Business Plan Case Competition upon Saturday, December 3rd, Rutgers Business School. BioNJ’s business plan case competition. Part of BioNJ’s broader strategic initiative. Health equity in clinical trialsto identify innovative approaches and successful models that can be used nationwide to foster the next generation of diverse clinical trial innovators, enhance clinical trial diversity, and expand health equity. was designed.
BioNJ believes that health equity in clinical trials will improve our understanding of drug safety and efficacy in underrepresented populations, expand access to medical innovations for these populations, and promote biopharmaceuticals. We believe it is important to increase dialogue and trust between industry, communities and the healthcare system. By discovering new approaches, leveraging new technologies, and developing new business standards to make clinical trials more accessible, we can work to create more agile, efficient, and patient-centric medical research.
8 teams competing for more than $20,000 With the prize money, I was tasked with developing a business plan that would define new solutions, applications or technologies that would help address this important and challenging problem. The team will identify specific types of health disparities building on proposed solutions, connect with community-based organizations, and better understand the real-world barriers that exist for selected populations to participate in clinical trials. The disease areas of focus for each team include Alzheimer’s disease, heart failure, multiple sclerosis, type 1 and type 2 diabetes, colorectal and cervical cancer, and oncology.
Each team consisted of 4-5 diverse and interdisciplinary students from MBA and other related graduate programs. (Click here to see the team’s resume.)
- Baylor College of Medicine, Northwestern University & Rice University
- Columbia University
- Johns Hopkins University
- Rutgers University
- temple university
- Tuck Business School dartmouth
- University of Arkansas Pine Bluff
- University of Pittsburgh
“There is an urgent need to bring more diversity to clinical trials to better serve patients and their communities, thereby helping to address health inequalities,” he said. Dr. Amadou Diarra, Senior Vice President, Global Policy, Advocacy and Government Affairs, Bristol-Myers Squibb. Member of the BioNJ Board of Directors and he is Chair of the BioNJ Health Equity in Clinical Trials Initiative“Only by improving the diversity of clinical trials can we advance our understanding of drug safety and efficacy for all populations. I am very proud of our team.” Solutions – help us advance our goal of leaving no patient behind.”
Live pitch presentations will take place throughout the day, A jury of industry experts:
- Nikea AtkinsonDirector, US Clinical Trials Diversity & Inclusion, Sanofi
- Syrah GreggsDirector, Technology Operations, Medidata
- Sharon HanlonHead of Clinical Trial Conduct and Enrollment, Bristol-Myers Squibb
- Maribel HernandezVice President, Clinical Operations & Special Projects, PTC Therapeutics
- Jack RosenbergManager, Investment and Business Development, TrialSpark
- Dell SmithCo-Founder and CEO, Acclinate
- lolita smithProgram Manager, Rare Disease Diversity Coalition, Black Women’s Health Imperative
- Matt WaltzRepresentative Director, TrialBee
“While prizes were ultimately awarded to three winning teams, each team provided new solutions and technologies to better serve patients, build community trust, and address gaps in healthcare delivery. It makes a difference for patients.” Paul HowardPh.D., Chair of the Steering Committee of the BioNJ Business Case Competition, Senior Director of Public Policy at Amicus Therapeutics“This is just the beginning of our efforts to share these suggestions more broadly.”
The white paper, including all presentations, will be published in April and will be presented at BioNJ’s highly acclaimed BioPartnering Conference, which attracts over 500 industry experts from around the world. The three winning teams were April 18th BioPartnering Conference and all students are invited to join the community.
The winning teams are:
- First place: Johns Hopkins University ($10,000) They focused their plans on increasing participation in clinical trials for the treatment of Alzheimer’s disease through community engagement strategies and the use of digital tools.
- Second place: Rutgers University ($7,000) They focused their plans on calculating health equity goals specific to prostate cancer clinical trial sites, using population health and real-world data analysis.
- Third place: Baylor College of Medicine, Northwestern University & Rice University ($3,500) They focused their plans on increasing Hispanic/Latino involvement in clinical trials by training community health workers from refugee and immigrant populations.
“BioNJ’s mission is to help its members help patients. It is with the vision of bringing health equity for all that BioNJ launched the Health Equity Strategies in Clinical Trials initiative. and the MBA Business Plan Competition is one of three important workstreams.” President of BioNJ Debbie Hart“In addition to thanking our extraordinary team for their commitment and time, Bristol Myers Squibb, Medidata, Amicus Therapeutics, PTC Therapeutics, Sanofi, Insmed, PsychoGenics, Thermo Fisher Scientific, Crowley Law and Rare Disease Diversity Coalition, Our expert judges, and our colleagues at the Kith Collective, have guided and supported us in moving this important initiative forward.”
For more information, Visit BioNJ.org/Health-Equity-Clinical-Trials.
About BioNJ
BioNJ is of Life Science Industry Association new jerseyFor nearly 30 years, we represent nearly 400 research-based life sciences organizations and stakeholders across the healthcare ecosystem, from the largest biopharmaceutical companies to early-stage start-ups.patient can’t wait®BioNJ is dedicated to ensuring a vibrant ecosystem where science is supported, companies are founded, medicines are developed, and patients have access to life-saving drugs.
BioNJ is recognized as a respected thought leader, an influential advocate, and a sought-after convener for the life sciences industry, working directly with both legislative leaders. Trenton When washington dc Advancing the life sciences industry, fostering healthcare innovation, and ensuring health equity and healthcare affordability. BioNJ’s mission is to make innovation the engine of medical breakthroughs by providing access to government and industry leaders, capital and state incentives, timely education programs, skilled talent, and value-driven purchasing programs. To empower our members to help patients by providing innovative resources. .
BioNJ is inspired by and honored to work with people committed to improving the lives of patients and their families around the world. For more information, please visit www.BioNJ.org.
media contact
Randy Bromberg
Vice President of Communications and Marketing
〇) 609-890-3185
C) 609-955-1067
[email protected]
SourceBioNJ
